BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30860438)

  • 21. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The estrogen pathway as a modulator of response to immunotherapy.
    Velez MA; Burns TF; Stabile LP
    Immunotherapy; 2019 Sep; 11(13):1161-1176. PubMed ID: 31361169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
    Cushman TR; Caetano MS; Welsh JW; Verma V
    Immunotherapy; 2018 Aug; 10(10):851-0. PubMed ID: 30073899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
    Gubens MA; Davies M
    J Natl Compr Canc Netw; 2019 May; 17(5.5):574-578. PubMed ID: 31117034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
    Lim SW; Ahn MJ
    Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A banner year for immunotherapy and targeted therapy.
    Carlisle JW; Ramalingam SS
    Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
    Bianco A; Perrotta F; Barra G; Malapelle U; Rocco D; De Palma R
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of immunotherapy in locally advanced non-small cell lung cancer].
    Levy A; Doyen J; Botticella A; Bourdais R; Achkar S; Giraud P; Du C; Naltet C; Lavaud P; Besse B; Pradère P; Mercier O; Caramella C; Planchard D; Deutsch E; Le Péchoux C
    Cancer Radiother; 2020 Feb; 24(1):67-72. PubMed ID: 32037126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
    Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
    Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy and Immunotherapy Combinations for Lung Cancer.
    Agrawal V; Benjamin KT; Ko EC
    Curr Oncol Rep; 2020 Nov; 23(1):4. PubMed ID: 33215306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis.
    Abdel-Rahman O
    Immunotherapy; 2019 Apr; 11(6):543-554. PubMed ID: 31135244
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy in Lung Cancer: From a Minor God to the Olympus.
    Russo A; McCusker MG; Scilla KA; Arensmeyer KE; Mehra R; Adamo V; Rolfo C
    Adv Exp Med Biol; 2020; 1244():69-92. PubMed ID: 32301011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
    Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
    Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy in the Treatment of Lung Cancer].
    Fiala O; Šorejs O; Pešek M; Fínek J
    Klin Onkol; 2017; 30(Supplementum3):22-31. PubMed ID: 29239189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.